Share on LinkedInShare on LinkedIn

ARTICLE · 29 NOVEMBER 2021

Covid-19 Vaccines And Pharmaceutical Disputes: How Can Arbitration Be Used To Resolve These Effectively?

Withers LLP
Withers LLP
Contributor
Withers LLP

Withers LLP

Withers is an international law firm focused on the personal, business and philanthropic interests...

View firm profile
Explore more from Withers LLP

If 2020 was the year of the coronavirus pandemic, 2021 is the year of vaccines. The distribution of vaccines and pharmaceuticals in general poses legal challenges and complex, ...

United KingdomLitigation, Mediation & Arbitration

If 2020 was the year of the coronavirus pandemic, 2021 is the year of vaccines. The distribution of vaccines and pharmaceuticals in general poses legal challenges and complex, multi-jurisdictional, and high value disputes may arise from it.

Arbitration can be an effective dispute resolution mechanism to solve potential disputes stemming from the distribution of coronavirus vaccines and pharmaceuticals - here we explore why.

Agreements that support the distribution of Covid-19 vaccines

To achieve greater equity in getting access to vaccines, the WHO, UNICEF, Gavi, and CEPI have created the Covax Facility. The Covax Facility, by connecting States in need of vaccines and manufacturers, ensures that countries will be guaranteed sufficient doses to protect a certain proportion of their population and lower-income countries can secure vaccines doses. Covax has signed agreements with States regulating the distribution of Covid-19 vaccines under the programme. These

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from